Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar1, Lijun Zhang1, Michael Untch2, Keyur Mehta3, Joseph P Costantino4, Norman Wolmark4, Hervé Bonnefoi5, David Cameron6, Luca Gianni7, Pinuccia Valagussa8, Sandra M Swain9, Tatiana Prowell1, Sibylle Loibl, D Lawrence Wickerham4, Jan Bogaerts10, Jose Baselga11, Charles Perou12, Gideon Blumenthal1, Jens Blohmer13, Eleftherios P Mamounas14
1US Food and Drug Administration, Silver Spring, MD, USA
2HELIOS Klinikum, Berlin, Germany
3German Breast Group, Neu-Isenburg, Germany
4National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
5Institut Bergonié INSERM U916 and Université Bordeaux Segalen, Bordeaux, France
6Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, UK
7San Raffaele Scientific Institute, Milan, Italy
8Fondazione Michelangelo, Milan, Italy
9MedStar Washington Hospital Center, Washington, DC, USA
10EORTC Headquarters, Brussels, Belgium
11Memorial Sloan-Kettering Cancer Center, New York, NY, USA
12Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
13St Gertrauden Hospital, Berlin, Germany
14MD Anderson Cancer Center Orlando, Orlando, FL, USA